公开(公告)号：US11926618B2

公开(公告)日：2024-03-12

申请号：US17753162

申请日：2020-08-20

Applicant: HINOVA PHARMACEUTICALS INC.

Inventor： Wu Du ,  Yu Li ,  Haibo Li ,  Yuanwei Chen ,  Chengzhi Zhang ,  Xinghai Li

IPC: C07D403/12 ,  A61K31/53 ,  A61P1/16 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  A61P5/14 ,  A61P5/16 ,  A61P9/10 ,  C07D253/075

CPC classification number: C07D403/12 ,  C07B2200/05

Abstract: A compound of formula (I) or an optical isomer thereof, and pharmaceutically acceptable salts, prodrugs, aquo-complexes or non-aqueous-solvent complexes thereof are provided. Experiments prove that, compared with a control compound MGL-3196, the compound of formula (I), which is obtained through specific substitution sites and specific substitution types, is higher in agonist activity to THR-beta and significantly improved in selectivity on THR-beta/THR-alpha. The compound can be used in preparing THR-beta agonist and drugs for treating adaption diseases (including dyslipidemia, hypercholesteremia, non-alcoholic steatohepatitis and non-alcoholic fatty liver disease) applicable to the THR-beta agonist.